J. Durant

3.8k citations
91 papers · 1.9k · 1 hit paper · h-index 21

Impact in

  • Virology top 0.5%
    • HIV Research and Treatment
  • Infectious Diseases top 1%
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

  • Infectious Diseases 38
    • HIV/AIDS drug development and treatment 28
    • HIV/AIDS Research and Interventions 13
  • Virology 22
    • HIV Research and Treatment 21
Co-authors
P. Dellamonica (54 shared papers)Philippe Clevenbergh (12 shared papers)Philippe Halfon (6 shared papers)N Montagne (5 shared papers)CAB Boucher (2 shared papers)Pere Simonet (2 shared papers)Pascal Del-Giudice (1 shared paper)R. Garraffo (12 shared papers)
Journals
Journal of Antimicrobial Chemotherapy (5 papers)Antimicrobial Agents and Chemotherapy (5 papers)HIV Clinical Trials (4 papers)AIDS (4 papers)Frontiers in Medicine (4 papers)
Partner nations
FranceUnited StatesBelgium

In The Last Decade

J. Durant

87 papers receiving 1.9k citations

J. Durant's Hit Papers

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial 1999 · 560 citations
5600+9+18Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 1999 The Lancet

Peers

J. Durant
Comparison fields: 5 of 103
  • Virology 802
  • Infectious Diseases 1.2k
  • Emergency Medicine 188
  • Hepatology 104
  • Epidemiology 296
Replace Joseph Timpone with:
Joseph Timpone United States
Richard Lalonde Canada
Kirk D. Miller United States
Katsuji Teruya Japan
Mindell Seidlin United States
Sylvie Abel Martinique
Powel Kazanjian United States
Huyen Cao United States
Dushyantha Jayaweera United States
Trevor Hawkins United States
J. Durant relative to Joseph Timpone United States Joseph Timpone's profile →
Citations per field
00.5×2×3×
Joseph Timpone · 1×
Citations per year

Countries citing papers authored by J. Durant

Since Specialization
Citations

This map shows the geographic impact of J. Durant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Durant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Durant more than expected).

Fields of papers citing papers by J. Durant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Durant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Durant. The network helps show where J. Durant may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Durant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Durant Line = papers co-authored together J. Durant links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
The Lancet ·J. Durant, Philippe Clevenbergh, Philippe Halfon, Pascal Del-Giudice, S Porsin, Pere Simonet, N Montagne, CAB Boucher, JM Schapiro, P. Dellamonica
Hit paper breakdown →		1999560
2
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study
AIDS ·J. Durant, Philippe Clevenbergh, R. Garraffo, Philippe Halfon, S. Icard, P. Del Giudice, N Montagne, Jonathan Schapiro, P. Dellamonica
2000182
3
Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up
Antiviral Therapy ·Philippe Clevenbergh, J. Durant, Philippe Halfon, P. Del Giudice, V. Mondain, N Montagne, JM Schapiro, CAB Boucher, P. Dellamonica
200091
4
PharmAdapt
AIDS ·Philippe Clevenbergh, R. Garraffo, J. Durant, P. Dellamonica
200276
5
Immune changes in post-menopausal osteoporosis: the Immunos study
Osteoporosis International ·Véronique Breuil, Michel Ticchioni, Jean Testa, C. Roux, P. Ferrari, J P Breittmayer, Christine Albert-Sabonnadière, J. Durant, F. De Perreti, A Bernard, Liana Euller‐Ziegler, Georges F. Carle
200968
6
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
AIDS ·Matteo Vassallo, J. Durant, Virginie Biscay, Christine Lebrun‐Frénay, Brigitte Dunais, M. Laffon, Alexandra Harvey-Langton, Jacqueline Cottalorda, Michel Ticchioni, Hélène Carsenti, Christian Pradier, P. Dellamonica
201347
7
Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir
HIV Clinical Trials ·Sylvie Chaillou, J. Durant, R. Garraffo, E. Georgenthum, Clotilde Roptin, Philippe Clevenbergh, Brigitte Dunais, V. Mondain, P.M. Roger, P. Dellamonica
200241
8
Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH
Journal of Hepatology ·Dominique Salmon, Firouzé Bani‐Sadr, Marc‐Arthur Loko, Hind Stitou, Anne Gervais, J. Durant, Éric Rosenthal, Yann Quertainmont, Karl Barange, Daniel Vittecoq, Michka Shoai-Tehrani, Muriel Alvarez, María Winnock, Jean Claude Trinchet, François Dabis, Philippe Sogni
201136
9
COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated
PLoS ONE ·Karine Risso, Francine Guillouet-de-Salvador, Laure Valério, Pascal Puglièse, Alissa Naqvi, J. Durant, Élisa Demonchy, I. Perbost, Éric Cua, Charles‐Hugo Marquette, Pierre‐Marie Roger
201732
10
Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice
Antimicrobial Agents and Chemotherapy ·Matthieu Prot, Laurence Héripret, Nathalie Cardot‐Leccia, Christophe Perrin, Myriam Aouadi, Thibaud Lavrut, R. Garraffo, P. Dellamonica, J. Durant, Y. Le Marchand‐Brustel, Bernard Binétruy
200629
11
Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study
Journal of NeuroVirology ·Matteo Vassallo, Brigitte Dunais, J. Durant, H. Carsenti-Dellamonica, Alexandra Harvey-Langton, Jacqueline Cottalorda, Michel Ticchioni, M. Laffon, Christine Lebrun‐Frénay, P. Dellamonica, Christian Pradier
201329
12
Effects of subinhibitory concentrations of vancomycin and teicoplanin on adherence of staphylococci to tissue culture plates
Antimicrobial Agents and Chemotherapy ·H. Carsenti-Etesse, J. Durant, José M. Entenza, V. Mondain, C. Pradier, E. Bernard, P. Dellamonica
199329
13
Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Carine Chaix, Catherine Grenier‐Sennelier, Philippe Clevenbergh, J. Durant, Jonathan Schapiro, P. Dellamonica, Isabelle Durand‐Zaleski
200028
14
Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation
HIV Medicine ·Matteo Vassallo, J. Durant, Christine Lebrun‐Frénay, Roxane Fabre, Michel Ticchioni, Signe T. Andersen, F. DeSalvador, Alexandra Harvey-Langton, Brigitte Dunais, Isabelle Cohen-Codar, N Montagne, Éric Cua, L Fredouille‐Heripret, M. Laffon, Jacqueline Cottalorda, P. Dellamonica, Christian Pradier
201527
15
Phenotyping of Intrahepatic and Peripheral Blood Lymphocytes in Patients with Chronic Hepatitis C
Digestive Diseases and Sciences ·Jean‐Louis Bernard, Jean Gugenheim, Marie‐Christine Saint‐Paul, Albert Tran, Guang Yang, Alain Doglio, Michel Ticchioni, C. Laffont, J. Durant, Alain Bernard, Patrick Rampal, Sylvia Benzaken
199725
16
Efficacy and safety of Buxus sempervirens L. preparations (SPV30) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial
Phytomedicine ·J. Durant, P. Chantre, G. González, J. Vandermander, P. Halfon, B. Rousse, D. Guédon, V. Rahelinirina, S. Chamaret, Luc Montagnier, P. Dellamonica
199824
17
Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions
AIDS ·Philippe Halfon, J. Durant, Philippe Clevenbergh, Hélène Carsenti, Linda Celis, Hacène Khiri, Koen De Smet, Annelies De Brauwer, Frank Hulstaert, P. Dellamonica
200323
18
Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study
PLoS ONE ·F. De Salvador-Guillouët, Charlotte Sakarovitch, J. Durant, Karine Risso, Élisa Demonchy, P. Roger, Éric Fontas
201523
19
The Serum Leucine Aminopeptidase Test
BMJ ·(unknown), Barbara Röper, J. Durant, Helen Miller
196023
20
Persistence ofPneumocystis cariniiAfter Effective Treatment ofP. cariniiPneumonia Is Not Related to Relapse or Survival Among Patients Infected with Human Immunodeficiency Virus
Clinical Infectious Diseases ·Pierre‐Marie Roger, (unknown), P. Puglièse, F. De Salvador, J. Durant, Y. Le Fichoux, P. Dellamonica
199822

About J. Durant

J. Durant is a scholar working on Infectious Diseases, Virology, Epidemiology, Pharmacology and Emergency Medicine, having authored 91 papers that have together received 1.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers), HIV/AIDS Research and Interventions (13 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers), HIV-related health complications and treatments (8 papers), Hepatitis C virus research (7 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Pneumonia and Respiratory Infections (4 papers). The work is most often cited by research in Virology (802 citations), Infectious Diseases (1.2k citations), Emergency Medicine (188 citations), Hepatology (104 citations) and Epidemiology (296 citations). J. Durant has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include P. Dellamonica, Philippe Clevenbergh, Philippe Halfon, N Montagne, CAB Boucher, Pere Simonet, Pascal Del-Giudice, R. Garraffo, P. Del Giudice and Jonathan Schapiro. Their work appears in journals such as Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, HIV Clinical Trials, AIDS and Frontiers in Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph TimponeBreakdown of academic impact, for papers by Richard LalondeBreakdown of academic impact, for papers by Kirk D. MillerBreakdown of academic impact, for papers by Katsuji TeruyaBreakdown of academic impact, for papers by Mindell SeidlinBreakdown of academic impact, for papers by Sylvie AbelBreakdown of academic impact, for papers by Powel KazanjianBreakdown of academic impact, for papers by Huyen CaoBreakdown of academic impact, for papers by Dushyantha JayaweeraBreakdown of academic impact, for papers by Trevor Hawkins